Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2021)
14 slides from Idt Australia's shareholder meeting presentation, Nov 16, 2021
Slide 1: IDT Australia Limited 2021 Annual General Meeting
For personal use only IDT AUSTRALIA LIMITED 2021 ANNUAL GENERAL MEETING 16 November 2021
Slide 2: Key Operational Highlights
Key Operational Highlights (1 July 2020 to present) For personal use only Restored IDT to Profitability FY`21 results reported the Company’s first operating profit since 2009 209.6% year-on-year increase in net profit after tax, from a loss of $1.9m in FY`20 to a profit of $2.1m in FY`21* Steril
Slide 3: FY21 Year In Review
FY`21 Year In Review* For personal use only COVID-19 Treatment and Vaccine Manufacture – TGA and Advance IDT’s Sovereign FDA accredited site at the ready Manufacturing Initiative Pushing Towards A Return To Continue To Execute IDT’s Operational Profitability Medicinal Cannabis Manufacturing Plan Fin
Slide 4: FY21 Financial Highlights
FY21 Financial Highlights First Operating Profit since 2009 For personal use only Year-on-year Revenue growth of 19.5% to $16.9 Year ended 30 June ($m) 2021 2020 Variance million (which includes $0.9 million of JobKeeper Results from operations including one time adjustments* receipts) Positive
Slide 5: Sterile Manufacturing: Sterile Readiness Agreement Finalised, Site Licence Secured
Sterile Manufacturing: Sterile Readiness Agreement Finalised For personal use only Site Licence Secured Sterile Facility Ready To Accept Contract Development and Manufacturing Content Sterile Readiness Letter Agreement finalised with the Australian Government Department of Health IDT’s flagship
Slide 6: Sovereign Manufacturing
Sovereign Manufacturing COVID-19 products manufactured for Australia’s National inventory For personal use only IDT manufactures Australia’s first locally developed mRNA COVID-19 vaccine candidate Project completed for the Australian Government Department of Health at the start of the pandemic to
Slide 7: mRNA Manufacturing Initiative
mRNA Manufacturing Initiative: IDT to become an mRNA Manufacturing Hub of Excellence For personal use only IDT has put forward its existing licenced sterile manufacturing facility in support of a submission to the Australian Government’s Onshore mRNA Manufacturing Capability: Approach To Market (A
Slide 8: Medicinal Cannabis
Medicinal Cannabis IDT continues to execute on its Medicinal Cannabis Manufacturing Plan For personal use only Process development has been completed for IDT’s medicinal cannabis resin extraction. IDT now progressing additional medicinal cannabis active pharmaceutical ingredient opportunities St
Slide 9: FY22 Year Ahead
FY`22 Year Ahead Strengthen IDT’s Engagement With For personal use only Demonstrate Capability With Government To Advance Successful COVID-19 mRNA The Company’s Sovereign Vaccine Manufacture Manufacturing Initiative Progress The Business To Execute On IDT’s Goal To Sustainable Profitability Become a
Slide 10: Corporate Snapshot
IDT Australia Limited Corporate Snapshot For personal use only -------------------------------------------------------------------------------------------- 75.5 cents Shares on issue 239,860,167 Options Nil Market Cap (as at 12 Nov 21) $118m Top 20 holders 61.5% of IC Year high 51 cents Year low 15
Slide 11: Board of Directors and Executive Team
IDT Australia Limited Board of Directors Executive Team For personal use only Mr Alan Fisher Chair Dr David Sparling CEO Experienced corporate advisor and public company director with a proven More than 20 years of pharma and diagnostics experience in CEO, Director and track record of implementing s
Slide 12: Q&A
Q&A For personal use only Q: How far along is the mRNA vaccine progressing?
Slide 13: Proxy Voting Summary
Proxy Voting Summary For personal use only Resolution Lodged For Lodged Open Lodged Against Total Available Votes %IC Votes Holders % Votes Holders % Votes Holders % 1 Adoption of Remuneration Report 52,410,787 99 97.86% 204,299 23 0.38% 940,525 18 1.76% 53,555,611 22.33% 2 Re-election of Hugh Burri
Slide 14: Disclaimer
Disclaimer For personal use only This presentation is for general information purposes only and should be read in conjunction with IDT Australia Limited’s Annual General Meeting on 16 November 2021. This presentation does not provide recommendations or opinions in relation to specific investments or